Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled maintenance study of olaparib after first-line platinum chemotherapy in BRCA-mutated advanced ovarian cancer
CTR20140831Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Jan 2015; status: active.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20140831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140831.